JD Health International Past Earnings Performance
Past criteria checks 4/6
JD Health International has been growing earnings at an average annual rate of 81.8%, while the Consumer Retailing industry saw earnings growing at 29.3% annually. Revenues have been growing at an average rate of 21.4% per year. JD Health International's return on equity is 8.9%, and it has net margins of 7.3%.
Key information
81.80%
Earnings growth rate
84.31%
EPS growth rate
| Consumer Retailing Industry Growth | 28.31% |
| Revenue growth rate | 21.37% |
| Return on equity | 8.93% |
| Net Margin | 7.32% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Narrative Update • May 04
6618: Online Respiratory Partnership And Firmer Margins Will Support Future Upside Potential
Analysts have raised their price target for JD Health International to HK$100.58 from HK$98.16, citing slightly firmer profit margin assumptions and a lower future P/E multiple in their updated valuation work. What's in the News CF PharmTech and JD Health entered into a cooperation agreement under which JD Health will act as the exclusive online launch platform for several new respiratory and rhinology products over the next three years, using its online platform and supply chain services for product launches and patient support (Key Developments).
Narrative Update • Apr 19
6618: New Respiratory Drug Partnership Will Support Future Margin And Traffic Upside
Analysts have trimmed their price target for JD Health International to HK$76.26 from HK$78.98, reflecting slightly updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News CF PharmTech and JD Health entered a three year cooperation in which JD Health will serve as the exclusive online launch platform for several new respiratory and rhinology products, covering areas such as allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease (Client Announcements).
Narrative Update • Apr 04
6618: Online Respiratory Partnership Will Support Dividend Prospects And Undervalued Outlook
Analysts have nudged their price target for JD Health International slightly lower to around HK$61.00 from about HK$61.20, reflecting updated views on fair value, revenue growth, profit margin, and future P/E assumptions. What's in the News CF PharmTech and JD Health entered into a cooperation agreement under which JD Health will be the exclusive online launch platform for several new respiratory and rhinology products over the next three years, covering online sales and patient service support (Key Developments).Narrative Update • Mar 20
6618: Higher Long Term Assumptions Will Support Dividend Decision And Undervalued Outlook
Analysts have nudged their fair value estimate for JD Health International higher from HK$58.07 to HK$61.20, citing updated assumptions around revenue growth, profit margin, and future P/E levels as the key drivers of the change. What's in the News Board meeting scheduled for March 5, 2026, to approve the annual results of JD Health International and its subsidiaries for the year ended December 31, 2025 (Key Developments) At the same meeting, the board will consider recommending a final dividend for the 2025 financial year, if any (Key Developments) Valuation Changes Fair Value: HK$58.07 to HK$61.20, a modest upward adjustment to the intrinsic value estimate.Narrative Update • Mar 06
6618: Higher Profitability Assumptions Will Support Upcoming Dividend Decision
Analysts have raised their HK$ price target for JD Health International to HK$58.07 from HK$42.21, citing updated assumptions regarding discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for Mar 05, 2026 to approve the annual results of JD Health International and its subsidiaries for the year ended Dec 31, 2025 (Key Developments).Narrative Update • Feb 20
6618: Refined Revenue And Margin Assumptions Will Support Future Upside Potential
Analysts have nudged their fair value estimate for JD Health International slightly higher to HK$98.16 from HK$97.73, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E expectations. Valuation Changes Fair Value: HK$98.16 compared with the prior HK$97.73, reflecting a very small upward adjustment in the model.Narrative Update • Feb 06
6618: Framework Agreement And New Partnerships Will Support Future Revenue Mix
Analysts have nudged their fair value estimate for JD Health International higher from about HK$95.95 to around HK$97.73, reflecting slightly different views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News JD Health International has called a special or extraordinary shareholders meeting for December 8, 2025, at 10:30 China Standard Time in Beijing to review and vote on a 2026 technology and traffic support services framework agreement with JD.com, Inc., including authorization for a director to execute related documents and actions (Key Developments).Analysis Article • Jan 25
Is JD Health International Inc. (HKG:6618) Potentially Undervalued?
Let's talk about the popular JD Health International Inc. ( HKG:6618 ). The company's shares saw a double-digit share...Narrative Update • Jan 23
6618: New JD Platform Agreements Will Support Future Margin And Traffic Upside
Analysts have nudged their fair value estimate for JD Health International higher to US$78.98 from US$76.81, citing slightly firmer revenue growth, improved profit margins and a modestly higher future P/E assumption in their updated models. What's in the News A special or extraordinary shareholders meeting is scheduled for December 8, 2025 at 10:30 China Standard Time in Beijing to review and approve a technology and traffic support services framework agreement with JD.com, Inc.Narrative Update • Jan 08
6618: New JD Platform Agreements Will Support Long-Term Shareholder Outperformance
Analysts have nudged their fair value estimate for JD Health International slightly higher, from about HK$76.29 to roughly HK$76.81, citing updated assumptions on revenue growth, profit margin and future P/E that together refine their overall view of the stock’s pricing. What's in the News JD Health International has scheduled a special or extraordinary shareholders meeting for December 8, 2025, at 10:30 China Standard Time in Beijing to vote on an agreement with JD.com for technology and traffic support services and related transactions (Key Developments).Narrative Update • Dec 24
6618: Framework Agreement Approval Will Support Stronger Future Revenue Mix
Analysts have raised their price target on JD Health International by roughly 9 percent, citing stronger expected revenue growth, modestly higher profit margins, and a slightly lower future earnings multiple. Together, these factors support an increase in estimated fair value to about $96 per share from approximately $88 previously.Narrative Update • Dec 10
6618: New CEO And Service Agreement Will Support Long-Term Outperformance
Analysts have nudged their price target for JD Health International slightly higher to approximately $76.29 from about $75.87, citing marginally stronger expectations for revenue growth that more than offset a modest trim to long term profit margin assumptions. What's in the News JD Health has called a special shareholders meeting for December 8, 2025 in Beijing to seek approval of a new 2026 technology and traffic support services framework agreement with JD.com, including authorization for directors to execute related documents and implementation steps (company circular).Analysis Article • Dec 08
Be Wary Of JD Health International (HKG:6618) And Its Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Narrative Update • Nov 25
6618: Leadership Transition And Key Partnership Are Set To Drive Outperformance
Analysts have raised their price target for JD Health International from $70.25 to $75.87. This reflects improved projections for both revenue growth and profit margins.Analysis Article • Nov 11
Is JD Health International Inc. (HKG:6618) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, JD Health International fair value estimate is HK$46.16 JD...Narrative Update • Nov 10
6618: Leadership Change Is Expected To Drive Stronger Performance Ahead
Analysts have modestly increased their price target for JD Health International, raising it from ¥70.10 to ¥70.25. They cite incremental improvements in projected revenue growth and profit margins as the reason for this adjustment.Analysis Article • Oct 28
With EPS Growth And More, JD Health International (HKG:6618) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Oct 27
Leadership Transition And Digital Healthcare Trends Will Shape Upcoming Performance
Analysts have raised their price target for JD Health International from approximately ¥68.78 to ¥70.10. This reflects slight improvements in expected revenue growth, profit margin, and valuation metrics.Narrative Update • Oct 13
AI And Omnichannel Expansion Will Shape Digital Healthcare Future
Narrative Update on JD Health International Analysts have raised their price target for JD Health International from $67.22 to $68.78, citing subtle improvements in revenue growth expectations along with modest adjustments to company profitability forecasts. What's in the News Mr. Enlin Jin has resigned as chief executive officer of JD Health International Inc., effective September 29, 2025, to devote more time to his family.Analysis Article • Sep 22
Is Now The Time To Look At Buying JD Health International Inc. (HKG:6618)?
JD Health International Inc. ( HKG:6618 ) received a lot of attention from a substantial price increase on the SEHK...Narrative Update • Sep 21
AI And Omnichannel Expansion Will Shape Digital Healthcare Future
The consensus analyst price target for JD Health International has edged higher, primarily driven by a notable increase in the forecast Future P/E multiple despite nearly unchanged revenue growth expectations, resulting in a new target of HK$67.22. What's in the News Upcoming board meeting to review and approve unaudited interim results for the six months ended June 30, 2025.Narrative Update • Aug 16
AI Integration With Jingyi Qianxun Will Improve Efficiency In Healthcare Services
Despite a moderation in consensus revenue growth forecasts, a higher future P/E multiple has driven the consensus analyst price target for JD Health International up from HK$45.99 to HK$49.62. What's in the News Board meeting scheduled to approve unaudited interim results for the six months ended June 30, 2025.Analysis Article • Aug 06
JD Health International Inc.'s (HKG:6618) Shareholders Might Be Looking For Exit
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 11x, you may consider JD...Analysis Article • Jul 07
JD Health International (HKG:6618) Could Be Struggling To Allocate Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...Analysis Article • Jun 22
Is There Now An Opportunity In JD Health International Inc. (HKG:6618)?
JD Health International Inc. ( HKG:6618 ) received a lot of attention from a substantial price increase on the SEHK...Analysis Article • May 22
Is Now The Time To Put JD Health International (HKG:6618) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
New Narrative • Mar 09
AI Integration With Jingyi Qianxun Will Improve Efficiency In Healthcare Services
Technological innovations and strategic partnerships aim to enhance customer experience, expand market share, and increase direct sales and margins.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How JD Health International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 73,441 | 5,375 | 12,767 | 1,634 |
| 30 Sep 25 | 69,274 | 5,048 | 12,295 | 1,528 |
| 30 Jun 25 | 65,106 | 4,721 | 11,824 | 1,422 |
| 31 Mar 25 | 61,633 | 4,441 | 11,320 | 1,376 |
| 31 Dec 24 | 58,160 | 4,162 | 10,815 | 1,330 |
| 30 Sep 24 | 56,462 | 3,390 | 10,568 | 1,293 |
| 30 Jun 24 | 54,764 | 2,618 | 10,321 | 1,255 |
| 31 Mar 24 | 54,147 | 2,380 | 10,165 | 1,241 |
| 31 Dec 23 | 53,530 | 2,142 | 10,008 | 1,226 |
| 30 Sep 23 | 53,576 | 1,930 | 9,903 | 1,212 |
| 30 Jun 23 | 53,621 | 1,718 | 9,798 | 1,197 |
| 31 Mar 23 | 50,179 | 1,049 | 9,384 | 1,132 |
| 31 Dec 22 | 46,736 | 380 | 8,969 | 1,067 |
| 30 Sep 22 | 42,003 | -7 | 8,542 | 1,023 |
| 30 Jun 22 | 37,270 | -395 | 8,114 | 978 |
| 31 Mar 22 | 33,976 | -734 | 7,911 | 935 |
| 31 Dec 21 | 30,682 | -1,074 | 7,708 | 893 |
| 30 Sep 21 | 27,463 | -6,702 | 6,799 | 813 |
| 30 Jun 21 | 24,243 | -12,331 | 5,890 | 733 |
| 31 Mar 21 | 21,813 | -14,783 | 4,923 | 671 |
| 31 Dec 20 | 19,383 | -17,234 | 3,957 | 609 |
| 30 Sep 20 | 17,007 | -11,901 | 3,346 | 537 |
| 30 Jun 20 | 14,631 | -6,567 | 2,736 | 466 |
| 31 Mar 20 | 12,737 | -3,769 | 2,389 | 402 |
| 31 Dec 19 | 10,842 | -972 | 2,042 | 338 |
| 31 Dec 18 | 8,169 | 215 | 1,458 | 218 |
| 31 Dec 17 | 5,553 | 179 | 1,002 | 123 |
Quality Earnings: 6618 has high quality earnings.
Growing Profit Margin: 6618's current net profit margins (7.3%) are higher than last year (7.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6618 has become profitable over the past 5 years, growing earnings by 81.8% per year.
Accelerating Growth: 6618's earnings growth over the past year (29.2%) is below its 5-year average (81.8% per year).
Earnings vs Industry: 6618 earnings growth over the past year (29.2%) exceeded the Consumer Retailing industry 18.4%.
Return on Equity
High ROE: 6618's Return on Equity (8.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/09 20:43 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JD Health International Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaomeng Zhuang | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Xipeng Feng | China International Capital Corporation Limited |